Ozempic

What the war in Ukraine has not achieved, Greenland has done. Europe has taken out its “commercial bazooka” against the US: Ozempic

by

For more than a year, Europe has become accustomed to living trapped in an uncomfortable balance where depends on the United States for its security through NATO, to sustain the Ukrainian effort and, ultimately, for the strategic architecture that has protected it since the Cold War. Now Greenland has done jump into the air part of the rhetoric. Europe and the counterattack. The crisis has erupted when Trump has returned to ignite a trade war using Greenland as an excuse and as an ultimatum: either some type of “agreement” that brings the island closer to the United States is accepted, or tariffs arrive first from 10% and after 25% a group of European countries designated by a minimal but symbolic gesture, to participate in Arctic maneuvers with Denmark. What until recently many in Europe preferred to interpret as bravado or negotiating tactics becomes an explicit message of political pressure that no longer leaves room for the fantasy of appeasement. And there appears the real change: what the Ukrainian war had not completely achieved (a frontal European response to American reprisals) Greenland is doing itbecause the coup is not against a geopolitical adversary but against alliesand because it puts Europe before a brutal choice: accept the blackmail and normalize it, or respond even if it hurts, even knowing that it continues to depend on Washington for its security and to contain Russia. The European bazooka. There is no doubt, the European reaction It is not born from enthusiasm, but from the feeling that there are no longer many other solutions: Greenland cannot be “handed over”, nor can Denmark sell an autonomous territory against the will of its population, and the very idea that an acquisition could be forced due to commercial threats opens a pandora’s box that affects the entire continent. In this context, Brussels dusts off for the first time his toughest tool, the so-called anti-coercion instrumentdesigned precisely to punish political pressures through rapid and forceful economic measures. on the table two paths appear that mark a leap in mentality: reactivate a package of tariffs worth of 93,000 million of euros already prepared and, if the escalation continues, go further of goods and target services, investment and even access to the European market for large American companies. The European message tries to be twofold, seeking a de-escalation that avoids an open clash, but making it clear that, if Trump turns trade into a method of extortion, Europe can also respond strongly. The crash that nobody wanted. The most disturbing thing about this episode is not only the economic impact of a tariff war, but the strategic fracture that it implies: Europe knows that a serious trade conflict with the United States will would infect NATOto Ukraine and the entire deterrence architecture against Russia. That is why the continent moves cautiouslycalling emergency meetings, preparing the ground for talks in Davos and even delaying previously agreed trade detente measures. But the core of the problem is that Trump is not negotiating a percentage or a clause: you are elevating a territorial objective to a national priority, presenting it as a requirement to “improve the security” of the Arctic, and implicitly denying that Europe can guarantee it. In this framework, Europe tries not to break the bridge, but assumes that it can no longer behave as if the bridge were indestructible. The sovereignty of Greenland. We’ve told it before: while Washington talks about “acquisition,” Greenland insists that its future belongs to them, that many they want more independencenot change flag. This point is essential because it explains why Europe doesn’t want to give in: it is not just about Danish pride or formalisms, but about sovereignty and democratic legitimacy, as well as an explosive precedent within the Union itself. The tariff threattherefore, works as an attempt to isolate Denmark and make it the weak link, although it has the opposite effect: it reinforces the idea that if you are attacked over a strategic issue, you will be respond as a block. And therein lies the paradox: instead of dividing, the pressure forces coordination, especially between Paris and Berlin, which push a harder line while others ask for time to see if Trump offers a “way out” before the punishment is activated. The “Ozempic bomb”. Amid the noise of bases, submarines and Arctic routes, the unexpected weapon appears: Denmark is not a commercial giant, but it exports products to the United States that directly affect the pocket and everyday lifeand that turns any tariff into a kind of political boomerang. The half of its sales Recent visits to Washington focus on medicines, vaccines, insulin and related products, because Novo Nordisk is there, the Danish economic engine and the factory of the global phenomenon Ozempic and Wegovy. That dependency converts Denmark in a kind of de facto “pharmaceutical state”: Your private growth and employment largely revolve around that industry, and any trade turbulence impacts both sides. If Trump makes these medicines more expensive, the blow will not stay in Europe: it enters the US market like health inflation and social unrest, just where the political margin is most fragile. And that is why Ozempic, more than a product, works as symbol of interdependence reality that makes a tariff war not just a lever, but rather a grenade. Lego and other reminders. The same effect is seen with Lego and other products Danes beloved in the United States, or with less visible but critical sectors such as hearing aids and certain medical equipment. In the real world, supply chains do not respect emotional boundaries: many parts are manufactured in different countries, assembled in others, and sold in markets that depend on global logistics. This means that tariffs punish not only the “enemy” exporter, but also companies, distributors and consumers. Trump can imagine squeezing Denmark to bend it, but the pressure leaks out in prices and disruptions in the US market itself, and also erodes the relationship with an ally that already offers military access in … Read more

“Why the ‘rebound effect’ has become the surgeon’s best ally against Ozempic

by

In the last two years, the GLP-1 receptor agonists like for example Ozempic either wegovy have gone from being drugs for diabetes to becoming the cultural and medical phenomenon of the decade for fight obesity. And such was its impact, that it was thought that surgery for obesity had come to an end, but the reality has been very different. The premise. The idea is quite clear: if I can take medication twice a month to lose weight… Why would I go into an operating room? A logical idea, especially given the risks that one always has when entering surgery, no matter how well controlled they are. But this enthusiasm of abandon the scalpel It is slowly being diluted, since according to the latest research, bariatric surgery is still superior to GLP-1 agonists and achieves much better results. The devastating fact. The study that has shaken the board comes from NYU Langone where researchers compared patients undergoing interventions such as gastric bypass with those who had taken Ozempic. The result was quite clear. Those who had undergone surgery managed to lose between 24 and 26% of their body weight, while patients on drugs lost an average between 5 and 6%. A result that does not agree with what was expected by pharmaceutical companies with their clinical trials in hand. But the problem is that the variable adherence to treatment It is once again a big problem in medicine. More data. The University Clinic of Navarra He also wanted to investigate in this field, doing a large study with 20,000 patients, concluding exactly the same thing: bariatric surgery surpasses GLP-1 agonists in total weight loss, reduction in BMI and body composition. The human factor. The great failure of a pharmacological treatment is undoubtedly the humans who are going to take it. And it is quite common in medicine for patients to forget to take a dose of their medication or even abandon treatment halfway through without any type of control. But luckily, the big difference between a pill (or injection) and surgery is that the second cannot be “forgotten.” The studies are clear in this sense: between 60% and 70% of patients They abandon GLP-1 treatment before the first year. Something that causes a great rebound effect which makes a patient return to their original weight, especially if they return to the same eating habits as before starting treatment with Ozempic or others. The difference. The reasons for reaching this point in treatment are varied: from persistent gastrointestinal side effects to the high monthly cost of treatment or the shortage. But the thing is that while stopping pricking yourself causes a rebound effect, bariatric surgery, although invasive, offers much more stable long-term results. Although logically he has many other problems behind him. Beyond the scale. The superiority of surgery is not measured only in waist centimeters. Science points through a systematic review published in JAMA Network Open This 2025 suggests that surgery is associated with lower overall mortality and a more drastic reduction in major cardiovascular events compared to drugs. And although GLP-1 has shown great benefits, the truth is that science indicates that surgery is still better in remission of type 2 diabetes with a minimal risk of mortality. Furthermore, despite the initial cost of the operation, in the long term surgery is cheaper for health systems than chronic drug treatment that costs hundreds of euros per month for life. A combined therapy. Despite all this, we are not in a war of one against the other, but the future points to an integration of both elements. In this way, strategies are already being explored where GLP-1 is used before surgery to reduce surgical risk in patients with extreme obesity, or after surgery as a rescue tool if the patient begins to regain weight years later. Even the WHO has begun to include these drugs in its comprehensive treatment guidelines, but emphasizing that they are one more piece of the puzzle, not a universal substitute. Images | David Trinks In Xataka | We have more and more research on the effects of Ozempic. And the problem is that we have more and more doubts

taking Ozempic to lose weight is a thing of the past, Wegovy is already in pills

by

The fight against obesity has just crossed a border that many were waiting for: that of comfort. Until now there are several medications approved to treat obesityas is the case with the famous Ozempicbut they had a problem: they were injections that had to be injected repeatedly. Now a big step has been taken by having a pill version of one of these options: wegovy. In the United States. The FDA, the drug regulatory agency in the United States, has given the green light to the oral version of Wegovy. Something that makes it the first drug in the GLP-1 family that does not require a weekly injection, but rather a simple daily intake of 25 mg. This move by Novo Nordisk is not only a change in the way of administration; It is a coup in a market valued in billions of dollars that until now relied on prefilled syringes and more complex cold chain logistics. The same results. The data supporting the approval of this new drug is actually quite good. Specifically, This new pill has been tested for 64 weeksseeing that those patients treated with this system strictly achieved a natural weight loss of 16.6%. This is something that is consistent with effectiveness in “real life”, where weight loss ranges between 13.6 and 14% The data being very similar to that obtained with the injectable version. And even other effects are also achieved, such as the reduction of major adverse cardiovascular events. Why has it taken? A priori, the logical thing is that these medications would have emerged as a simple pill that is taken daily, instead of an uncomfortable injection that also requires cold to be preserved. The problem in this case is that semaglutide (the component of the drug) it is a protein that the digestive system tends to destroy with its acids before reaching the bloodstream. This meant that it had to be administered directly into the blood to avoid this problem. Now, the Novo Nordisk company has managed to protect the molecule from gastric acids, although without reducing the classic side effects. In this case, patients have reported diarrhea and vomiting when taking this medication, as was already the case with the injection. Price and availability. The announcement has had a great impact, making the pharmaceutical company’s shares will shoot up more than 7%and much more that will surely do so when it is launched in the United States starting in January 2026. For the rest of the countries like Spain, it depends on the approval of local regulatory agencies that must verify the studies that support this pill to check if its effects are real. But the most disruptive may be the price. Novo Nordisk has suggested a starting dose of 1.5 mg at a cost of $149 per month. This is a considerably lower figure than current injectables, probably due to logistical savings, since manufacturing an injection is not the same as manufacturing a blister of pills. Its importance. With this pill, the barrier to entry that many patients had was eliminated: needle phobia. Although there is still the price issue ahead. In addition, it simplifies distribution and storage, alleviating supply problems that have been a major drawback in recent years. We are at the beginning of the “oral era” of GLP-1, where the competition (such as Eli Lilly) is already working on their own versions. For now, Novo Nordisk has taken the lead in the race to conquer the medicine cabinets of millions of people with obesity. It’s still not a miracle. Like the injection, this pill does not make you lose weight by ‘the grace of God’, but rather requires a very important personal process. The tablet can make us eat less, but if you stop the treatment we return to the beginning, little will have been done during the journey in which you have been medicated. Images | Haberdoedas danilo.alvesd In Xataka | For many people, food is a source of intrusive thoughts. Ozempic is able to “silence” them

Ozempic came to simplify the relationship with food. Christmas is proving how wrong we were

by

Christmas has always been a delicate territory for the relationship with food. Family reunions, full tables and seemingly harmless comments turn these dates into a kind of silent examination of the body. For years the answer was the express diet before the holidays. Today, in many cases, the conversation revolves around a weekly injection. In the United States, there were cases of people skipping their Ozempic shot to enjoy Thanksgiving, according to The Wall Street Journal. The phenomenon in Spain is less visible, but the question is inevitable: what will happen this Christmas and what consequences could this jump have? Ozempic in Spain: a discreet use on the rise. Ozempic or other drugs based on semaglutide or tirzepatide have restricted access, require a prescription and, in theory, priority for patients with diabetes. Even so, its use for weight loss exists and is increasing, especially in the private sector. “In consultation, doubts begin to appear about what to do with these drugs on special dates such as Christmas,” explains Dr. Víctor Bravoendocrinologist interviewed in Xataka. “It is not always verbalized as ‘I’m going to skip the dose’, but the idea of ​​’stopping a little’, ‘adjusting’ or ‘I’ll see after the holidays’ does appear.” The difference with the United States is one of degree, not nature. There the debate It is public and massive. Here it begins more quietly, but with the same roots: fear of losing control, social pressure and a complex relationship with food that the holidays intensify. Understand well what it is. Ozempic is neither a one-time appetite suppressant nor a cosmetic aid. Its active ingredient is semaglutide, a drug that replicates the action of the hormone GLP-1 that the body releases after meals. This hormone intervenes in the regulation of insulin and satiety signals, so the treatment reduces appetite and prolongs the feeling of being full. “This is important to understand well,” emphasizes Laura Albó, psychologist specialized in eating disorders and EMDR traumawith whom we have chatted in Xataka. “It is not a pill that takes away the desire to eat only that day. It is a treatment that modifies the signaling of hunger and satiety on a continuous basis. Interrupting it is not neutral.” Besides, as recalled by the scientific reviews recently analyzed by the WHOthese drugs work to lose weight, but they are not free of side effects nor is their long-term impact still known with certainty. Nausea, digestive discomfort and, in some cases, abandonment of treatment are part of the real picture. The Christmas dilemma: enjoy without losing control. One of the most repeated promises of GLP-1 is peace of mind: eating without fear of overflowing. Precisely for this reason, Christmas is experienced as a paradox. “What we observed is that many people consider these dates as an exception,” explains Albó. “It’s the same mental scheme of diets as always: now I can relax, now it’s time to enjoy, and then I’ll control myself again. The tool changes, but not the logic.” According to the psychologist, the conflict is not so much in the amount of food as in the meaning attributed to it. “When someone feels like they need to skip treatment to enjoy themselves, they are reinforcing the idea that eating with pleasure and eating with control are incompatible. And that dichotomy is a clear basis for eating discomfort.” From a medical point of view, Dr. Bravo agrees that expectations are often unrealistic. “Some people hope that by stopping the medication for a few days the body will function as before the treatment. But what usually returns is not a ‘normal’ relationship with food, but a sharp increase in hunger and constant worry about eating.” As we have previously mentioned, in the United States, some patients delayed the weekly dose to arrive with a greater appetite for holiday meals. But Laura Albó warns that this approach displaces the problem: “It’s not just physical hunger. It’s mental noise, paying attention to the menu, the dessert, how much is left. Just what many people had managed to silence.” What happens if you skip Ozempic? From a physiological point of view, interrupting or delaying a dose can cause a return of hunger that is more intense than expected. “The body once again receives signals that had been dampened for weeks or months,” says the endocrinologist. “This does not mean that the person eats ‘normal’, but rather that they may experience a sharp increase in appetite and greater difficulty in self-regulation.” But the impact is not just physical. “On an emotional level, the effect is usually a swing,” adds Laura Albó. “First the idea of ​​permission appears—now I can eat—and then, if the person feels that it has gone too far, guilt and shame come. This cycle is well known in consultations.” Scientific evidence supports this risk. Studies on hormonal regulation of appetite show that the body’s adaptations after weight loss do not disappear immediately. Skipping treatment does not eliminate that vulnerability; in some cases it intensifies it. So what do the experts recommend? There is no single answer, but there is clear consensus among the professionals consulted: Do not make impulsive or guilt-based decisions. Do not use medication as punishment or as permission to eat. Maintain basic schedules and routines to avoid arriving extremely hungry. Understand that two or three meals do not determine the success or failure of a treatment. “The important thing is not to turn Christmas into a test,” summarizes psychologist Laura Albó. “Two meals do not change a body, but they can greatly alter the emotional state.” For its part, Dr. Victor Bravo He insists that any adjustment should be discussed with the professional who prescribes the treatment: “Not so much because of the specific meal of a day, but because of what that decision can trigger later.” The role of the family: the noise that cannot be seen. Although the focus is usually on who takes the drug, the environment has a decisive weight. Comments such as “how little you … Read more

The “my cat is fat” problem is so common that the industry has come up with an idea: “Ozempic for cats”

by

In just a few years, drugs such as Ozempic, Wegovy or Mounjaro have gone from being discreet treatments for diabetes to become a great social phenomenon. His promise—lose weight through a simple weekly injection—has opened a new chapter in human medicine. Now, this pharmacological revolution is beginning to expand beyond people: cats could be the next to receive an adapted version of these treatments. Goodbye fat cats. Okava Pharmaceuticals, a San Francisco company dedicated to chronic diseases in companion animals, has started a pioneering clinical trial called MEOW-1whose objective is to evaluate the safety and effectiveness of OKV-119, a subdermal implant capable of releasing exenatide—a GLP-1 agonist—sustained for months in overweight or obese cats. The intervention aims to simplify a treatment that, in humans, usually requires weekly injections. Here, everything comes down to a single gesture. “You insert the capsule under the skin, and six months later you come back, and the cat has lost weight. It’s like magic,” says Chen Gilor, the veterinarian responsible for the study. speaking to the New York Times. A pioneering study. Okava’s interests did not arise out of nowhere. Prior to MEOW-1, the company evaluated prototypes of the implant in two preliminary studies. A work published in Frontiers in Veterinary Science demonstrated that the OKV-119 implant could be easily implanted and removed, that it was well tolerated, and that its plasma levels of exenatide correlated with weight reduction in healthy cats for more than one month. Subsequently, research published in BMC Veterinary Research delved into this line: they implanted five cats with the designed prototype for 84 days, what they observed is that during that period stable levels of exenatide were maintained and four of them reduced at least 5% of their body weight, along with a lower caloric intake. These results motivated the move to a trial in real obese cats, which Okava plans to run this summer. According to the companyMEOW-1 will be the first formal feline weight loss study based on GLP-1 agonists. How does the implant work? OKV-119 uses the NanoPortal platformdeveloped by Vivani Medical. According to scientific studiesthis technology uses: a titanium reservoir, a membrane with nanotubes that regulate the passage of the drug, and a system designed to ensure a constant and prolonged release without pronounced peaks. Furthermore, this type of administration allows us to overcome the main difficulty associated with GLP-1 in veterinary medicine: lack of adherence. Studies indicate that giving repeated injections to a cat is complex, stressful and can drastically reduce the continuity of treatment, ithe same as what happens in people with injectable drugs. The implant seeks to solve that problem with an approach one-and-done: a subdermal insertion in a veterinary office, without daily intervention by the caregiver. According to The New York Timesthere are veterinarians who already use human GLP-1 agonists off-label in diabetic cats, but its cost and need for frequent administration limit its use. Hence the relevance of a device that could keep the medication active for half a year. But only in cats? Although MEOW-1 focuses exclusively on felines, Okava and Vivani have confirmed an expansion of the project to dogs, another species with obesity rates greater than 50% in the United States. The company states that its goal is to reproduce in dogs the metabolic effects observed in cats: improved insulin sensitivity, reduction in fat mass and greater energy efficiency. With the expectation that these changes may even promote healthier aging. With both markets, the commercial potential is evident. According to estimates collected in Xatakathe global human obesity drug sector could exceed $100 billion by 2030. Veterinary medicine would be a new frontier. Feline obesity is a global epidemic. The interest in an “Ozempic for cats” is not a whim. It is an answer to a growing problem. A review published in Journal of Feline Medicine and Surgery places the prevalence of feline overweight between 40% and 63%, although it continues to increase. When you ask veterinariansthe same patterns almost always appear: cats that live exclusively indoors, very little movement, food available all day, too many treats, sterilization and a very common problem: many owners are not aware that their cat is gaining weight. The consequences are not minor: insulin resistance, diabetes, joint problems, urinary diseases, anesthetic complications and liver disorders, in addition to a reduction in life expectancy. And the latest evidence goes even further. A proteomic analysis that evaluated 288 proteins in cats with obesity found important changes in inflammatory processes, in the complement system, in coagulation pathways and in lipid metabolism. In other words, feline obesity affects the entire organism, it is not just a “fat cat.” Many open questions. Although MEOW-1 is moving forward with positive expectations, mass adoption of an “Ozempic for cats” is far from a fact. The first unknown is the price. In humans, GLP-1 cost several hundred euros a month, and it is not clear whether a semi-annual release veterinary implant will really be affordable for the majority of caregivers. Cost could become the main barrier to entry, especially considering that feline obesity is a common problem, but not always perceived as a health priority. The second uncertainty has to do with the available scientific evidence. So far, studies on OKV-119 have been preliminary and with extremely small samples (between 5 and 15 cats). They work, yes, but we still don’t know what will happen on a large scale, or how animals with diseases or in varied home environments will respond. Finally, there is the question of scientific independence. For now, all published studies on OKV-119 come from teams linked to Okava or Vivani, the companies developing the implant. There is no independent, large-scale evidence, and this matches a pattern already observed in human GLP-1where much of the initial research is driven by the industry itself. A new era in feline medicine? The questions surrounding this new milestone in the treatment of feline obesity are piling up: will these preliminary results be enough to justify regulatory approval? Will caregivers change … Read more

We already had an ozempic to lose weight, now someone has created one for the eternal youth: NAD+ promises

by

Of the six -digit operations In elite operating rooms to luxury serums That they promise to erase wrinkles in minutes, the eternal youth industry has always played with the same idea: that somewhere there is a shortcut. But what if the secret was not in a cream or in a scalpel, but in a tiny molecule that lives in each of our cells? This is how NAD+is presented, the coenzyme that has gone from being a laboratory concept to become the new biohacking grail. The ozempic of being young. As happened with the GLP-1 drugs in The obsession with thinnessNAD+ has become the aspirational shortcut towards youth. Hollywood and the aesthetic elite have embraced him within the call “Invisible luxury”: undetectable results, continuous maintenance and therapies that combine apparatus with cosmetic biology. In that stew of mass access, supplements and “shots” of NAD+ they occupy the biohacking story. From Hollywood A Amazon. A couple of years ago, Hailey Bieber and Kendall Jenner They popularized Intravenous NAD+therapies, a format that Miami and Dubai clinics sell as an energy and anti -aging “booster”. But it is not just celebrity thing: a search is enough on Amazon to find NMN or NR capsules that promise to raise cell levels. The problem is that, As The New York Times has warnedthe scientific evidence that supports these habits is still weak. In addition, what appears on the label often does not match what is in the bottle. A study led by the gerontologist Andrea Maier detected deviations of up to 100% in the real content of supplements, regardless of brand or price. Shining the NAD+. Better known as Nicotinamide adenine Dinucleotide, is something like the spark that allows our cells to work. It is everywhere, from the muscles to the brain, and According to the University of Navarra Clinic Participate in such critical tasks as producing energy, repairing damaged DNA or activating syruches, proteins linked to aging. The problem is that, over the years, NAD+ levels plummete and begin to relate to memory loss, muscle weakness and an increase in the risk of diseases associated with age. Therefore, raising those levels by precursors such as NR or NMN can keep mitochondria and favor cell longevity. Initial essays, collected by the confidentialThey have documented improvements in memory, movement and metabolism. However, they are small studies and experts They agree that they are missing Essays to convert the promise into solid evidence. Experts ask for prudence. Enthusiasm coexists cautiously. According to the webmd medical portalnicotinamide is safe to 900 mg per day, but high doses can cause headaches, fatigue, gastrointestinal problems or enzymatic alterations. In the case of nicotinic acid, another form of related vitamin B3, can cause redness and decreases in voltage even in moderate doses. The University of Navarra Clinic Explain that Supplements can interact with medications that affect liver or coagulation, so it is recommended to use them only under medical supervision. In a more concrete way, they probably do not damage in moderate doses, but there is also no certainty that it is worth taking risks for something that still has no macros studies. A society in search of shortcuts. NAD+ fever fits into a broader cultural context: obsession with shortcuts against aging. Hollywood has gone from “Frozen faces” from Botox to the “Liquid surgery” And luxury invisible treatments, while the rest of society consumes supplements, Collagen powder and Digital filters as affordable substitutes. And perhaps that distance reveals something deeper: our obsession with shortcuts against the inevitable. The eternal youth industry blooms because we live terrified at the passage of time, as if aging were a failure that must be corrected. But old age is not an anomaly: it is the only certainty we share. Perhaps the real question is not how to avoid it, but why it costs us so much to accept it. Meanwhile, science continues to remember what it works –move, sleep well, Eat better– Although it never sounds as glamorous as a molecule that promises to stop the clock. Image | Pexels and Freepik Xataka | The elixir of eternal youth exists and we are seeing it in real time: luxury surgeons “at $ 100,000 the session

Novo Nordisk has found the formula to recover the profitability of Ozempic: fire 9,000 employees

by

The Pharmaceutical Novo Nordisk, manufacturer of Ozempic and Wegovy, is living one of the biggest turbulence in its history recent. After losing the favor of investors and a good part of its stock market value in the last year, the company has announced a drastic reduction of workforce that affects 9,000 employees around the world: 11.5% of the total staff. 9,000 layoffs, most in Denmark. Novo Nordisk has confirmed Through a statement the cut of 9,000 jobs in the coming years, a figure that represents 11.5% of its template globally, composed of 78,400 employees. Denmark, a country of origin of the pharmaceutical, will be the country that will receive the greatest impact of that measure, accumulating about 5,000 of the planned dismissals. The firm has not yet specified how layoffs will be distributed in the rest of international venues, since the decision is subject to “to the relevant consultations in accordance with local labor legislation.” The multinational has remarked that “this is a global transformation, and each country, headquarters or region will be affected differently,” underlining the international dimension of its labor adjustment process. Multimillionaire savings and business reorganization. With this cut, the pharmaceutical enhance business lines centered on the Research for new treatments For diabetes and obesity, putting greater emphasis on commercial initiatives. It should be remembered that, in origin, both Ozempic and Wegovy were born as a new treatment to enhance insulin generation, but its satiating effects turned out to be much more profitable. Among the objectives mentioned in the official statement include organizational simplification, the increase in speed in decision making and the reallocation of resources towards the strategic fields of the company. According to the statement, Nordisk “must evolve in a market that has become more competitive and consumer oriented”, which implies “a change of mentality and approach that allows us to be faster and faster.” According to published by Reutersthe company would have asked its employees to return to its full -time offices within that same restructuring and optimization plan for its operations. Bursatile bleeding as a trigger. The collapse of the stock market suffered by Novo Nordisk during the last year is the main trigger for the adjustment measure. As published the BBCthe price of your shares was reduced by 60% Since June 2024, losing 430,000 million in stock market capitalization. The situation was especially aggravated on July 30, with a decrease in 23% in a single day After the downward review Growth forecasts and the announcement of the relay in the executive direction. The official presentation of Mike Doustdar as the new CEO of the company has marked the beginning of this stage of changes, which aims to recover the confidence of investors and redefine the corporate culture of the company. Its first measure has had a positive impact on the markets, and after the announcement of the template cuts the value of its shares has increased by 3%. In Xataka | If you want a “miracle” medication to lose weight, you no longer resort to Ozempic: the competition is starting to overcome it Image | Flickr (News Oresund, Chemist4u)

WHO wants to improve access to drugs such as Ozempic. Now they are on their list of essential medicines

by

Ozempicthe treatment against diabetes that reached the fame converted into medication for weight loss has lived for a convulsive years that could have resulted in a “death for success.” The popularity of the drug created a severe supply problem. Now, the World Health Organization (WHO) has taken a new step to improve access to the drug, especially in less favored countries. Updating the list. The (WHO) has up to date its model list of essential medicines (EML). The new list Includes GLP-1 drugswhich emulate the peptide that gives its name to the group, the family of treatments flagging by Ozempic. According to the international organism, this inclusion aims to improve access to the popular drug, especially in countries with less income. The extension covers other drugs, such as treatments against various types of cancer, against cystic fibrosis, psoriasis, hemophilia and other blood -related disorders. In total, the new list now incorporates 523 essential medicines. The extension It also affects the WHO model list of essential pediatric medicines (EMLC), which now has 374 treatments. The “GLP-1 family”. The incorporation of the GLP-1 drugs includes compounds such as semaglutida (the Ozempic base and Wegovy), the dorara and the liraglutid Zepbound and Mounjaro). These types of compounds act as agonists of the hormone receptors that we know as LPG-1, or Peptide similar to type-1 glucagon (although some also work as agonists of other hormones). This hormone is produced and segregated by our body after meals and meets Two key functions. On the one hand, it informs the pancreas of the intake to reinforce insulin production, hence these compounds help people with diabetes. The second function of this peptide is the one that makes these useful drugs to lose weight. The LPG-1 also transmits information to our brain, information that it interprets as the feeling of satiety. Improve access. According to WHO explains in a press releasethese drugs can help people with type 2 diabetes improve their glycemic control, but they are also able to “reduce the risk of cardiovascular and renal complications, favor weight loss and even reduce the risk of premature death, especially if they have renal or cardiac failure ”, a fact that would be based, at least in part, the decision. As details in the international organism, the price of these drugs implies significant access to them. Its inclusion in the list aims to expand this access, prioritizing patients who can benefit the most while fostering competition through genericians capable of bringing these medications to primary care, “especially in unattended areas.” “A large part of the direct spending of families in noncommunicable diseases is destined for medicines (…). To offer equitable access to essential medicines, an equal response of health systems, a strong political will, multisectoral cooperation and programs focused on people who allow everyone,” detailed in the press release Deusdedit Mumbangizi, Director of Policies and Standards for Medicines and Health Products of the WHO. Expanding in the fight against cancer. The expansion of WHO lists also include several cancer treatments, including several antineoplastic, drugs that seek to avoid the formation of growth that can become cancerous or neoplasms. Among these drugs are inhibitors of the immune control point PD-1/PD-L1, which help our immune system To recognize and attack with cancer cells. In Xataka | China is the great candy of pharmaceutical thinning. And there is a wild race for selling the new ozempic Image | Chemist4u / Yann Forget

The great alternative to Ozempic is LPG-1

by

Despite the great promise to quickly lose weight thanks to a minimum puncture, many people still reject the idea of injecting medicines such as Ozempic either Wegovy. In response, great pharmaceuticals refine their strategies with based on pill versions In the GLP-1 receiver. However, the first figures raise an awkward question: What will be willing to sacrifice patients in exchange for not pricking? In the test phase. The Eli Lillly company has presented the results of its clinical trial with Orforglipron, a daily pill designed to induce weight loss. According to data published by The Washington PostThe participants who took the highest dose reduced their body weight on average after 72 weeks, which is equivalent to about 12 kilos, compared to less than 1 % in the placebo group. It is a clinically significant result, but lower than that reached with its strut -in -lawy -led drugs – commercialized as Mounjaro or Zepbound -, with which in a previous trial a 22.5 % weight loss was achieved in the same period. The company said it will request the regulatory approval before the end of the year and trusts that the comfort of the pill compensates its lower power. Pfizer was the first. The race for the GLP-1 pills is not exclusive to Lilly and Novo. As we collected in Xatakathe American pharmacist Pfizer has announced advances in the development of Danuglipron, an agonist of the GLP-1 receiver who, unlike Ozempic, Wegovy or Zepbound, would be administered only orally. The drug is in a new phase of clinical trials to evaluate its safety and pharmacokinetics, with the aim of adjusting it as a daily taking treatment. According to the company, the tests have already included 1,400 healthy adults in an open and random essay. Preliminary data promoted Pfizer’s actions 2 % in the stock market, But analysts cited by Xatakalike Uumer Raffat for Fortune, warn that advances seem “tentative” and that, in the best case, the medicine would reach the market in 2028. There are more bets. The Ozempic and Wegovy manufacturer also does not want to stay out of the transition to the pills. As we have reported in XatakaNovo Nordisk awaits an FDA decision about its oral version of Semaglutida before it ends 2025. In parallel, its candidate Cagrisema – a combination of semaglutida and cagrilintida – achieved in clinical trials an average weight reduction of 22.7 %, slightly below the 25 % that the company had announced as an initial objective. A fact that, although raised, shows that even in the new generation of oral treatments, the power can remain below expectations. Comfort against efficacy. GLP-1 medications have shown unprecedented results in the fight against obesity, but the route of administration marks differences. As they have detailed in Washington Postweekly injection of tirzepatida or semaglutida allows to reach more stable levels of the blood molecule and, with it, greater weight reductions. On the other hand, the oral route requires formulas that resist digestion and are effectively absorbed, which raises technical limitations. In the case of Orforglipron, the consequence is a weight loss lower than that of its injectable equivalents. The big question is whether patients and doctors will be willing to prioritize comfort over effectiveness. For many, a 12 % reduction in body weight remains clinically relevant and can mean substantial improvements in cardiovascular and metabolic health. But in a market in which each percentage point counts, the comparison with 20-22 % of the injections could condition their adoption. A millionaire market with access barriers. The interest in these therapies is not accidental. According to estimates collected by this meansthe global market of obesity medications could exceed 100,000 million dollars annually in 2030. In addition to weight loss, LPG-1 improve glycemic control and reduce cardiovascular risk, which expands its clinical attraction. However, the price remains an obstacle. According to data cited in this mediumOzempic costs around $ 600 per month in the United States, compared to 59 euros in Germany. So the debate for future oral versions is open. A future with more options and more questions. With Lilly, Pfizer and Novo Nordisk preparing their releases, GLP-1 pills could expand the scope of obesity treatments, especially among those who reject injections. But the transition will not be automatic. In a market where efficacy has been the main sales argument, the arrival of more comfortable but potentially less powerful options will force to rethink strategies, prices and expectations. And although the interest is evident, the question remains the same: how much is it worth, for doctors and patients, the simple fact of not having to use a needle? Image | Unspash and Unspash Xataka | If you want a “miracle” medication to lose weight, you no longer resort to Ozempic: the competition is starting to overcome it

Novo Nordisk has been made gold with Ozempic but knows that it will not last forever. So you already have two substitutes

by

The slimming drug market does not stop enlarging but the competition for taking the largest portion in this growing “cake” It is fierce. The American pharmaceutical Ozempic. Now the European company tries to recover its advantage. And he does it with a double ad. Roadmap. Little by little Let’s get to know more details About the drugs that Danish pharmaceuticals Novo Nordisk wants to give relief to Ozempic and Wegovy, their star treatments based on semaglutida. Different compounds, different analogues. Semaglutida is the active compound on which medications such as Ozempic and Wegovy are based. This formula, initially devised as diabetes treatment, works by serving as analogous to the GLP-1 hormone (peptide similar to type 1 glucagon), it is what is known as an agonist of hormone receptors. LPG-1 is a hormone that fulfills two functions in our body by transmitting the message that we have fed on the pancreas, activating insulin production; and to the brain, unleashing the feeling of satiety. This second function is the one that has led to the success of Ozempic and similar drugs transforming into weight loss treatments and thus achieving its present success. The new Danish pharmaceutical formulas are based on compounds that act similarly to the semaglutida, but with characteristics that make them own and, at least in principle, superior. Cagrisema Of the formulas proposed by Novo Nordis, Cagrisema is perhaps the one in a more advanced state of development. The drug is based on the semaglutida and the Cagrilintidaa compound that serves as an analogue of amiline And also of the Calcitoninacting as agonist of some of the receptors of these hormones. Amiline is a hormone similar to insulin, also segregated by the pancreas and also used for glycemic control in our body. Cagrisema therefore works as a double (or triple) analogous, however The first results They were not as positive as some expected. New data. Now we have the remaining data of the essays by the company to derter the efficacy of the drug. According to Explain Reutersthe study data showed a weight reduction of about 23% in overweight adults after 68 weeks; and 16% weight loss among people with diabetes. Those responsible for the company gave data on moderate adverse effects, which affected 79.6% of the participants; and serious, which affected 9.8% (with 6% of patients abandoning the trial). Those responsible expect the arrival of Cagrisema to the market towards the beginning of 2027. Amicretin. Last week Novo Nordisk He also announced The implementation of phase 3 tests of amicretin, one of the compounds designed to contain the legacy of the semaglutida. According to the company itself, this compound is a unimolecular agonist of prolonged action of the GLP-1 receptors and those of the amiline. One of the great novelties is that this formula is being tested not only to evaluate its subcutaneous administration but also its consumption orally. Phase 3 of clinical trials usually seeks to complete and complement the information obtained in previous trials in addition to studying additional issues such as dosage or efficiency compared to other formulas. The other novelty of Novo. In addition to the new formulas, Ozempic has also monopolized attention in the last week. He did it since the European Medicines Agency (EMA) I went on to recommend this drug as treatment for peripheral arterial disease, In Xataka | Generic medications have been trying to site Ozempic for years. And now they have found a shortcut in Canada Image | Chemist4u / News Oresund

Log In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.